Physician profile
Mir Ali
NPI 1518237585
$874.00
in general payments reported to CMS, 2019-2025
15 companies · $228 in 2025
The $228 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $480 · 2020: $63.65 · 2022: $80.53 · 2024: $21.79 · 2025: $228.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $250.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $249.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $411.02 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $112.28 | 2019-2024 | Enhertu |
| Imbed Biosciences INC. | $63.05 | 2022 | |
| Novartis Pharmaceuticals Corporation | $46.57 | 2025 | |
| Emd Serono, INC. | $40.05 | 2025 | |
| Servier Pharmaceuticals LLC | $32.04 | 2025 | |
| Genentech USA, INC. | $31.63 | 2025 | Polivy |
| E.R. Squibb & Sons, L.L.C. | $21.19 | 2025 | Opdivo |
| Ipsen Biopharmaceuticals, INC | $20.52 | 2025 | Onivyde |
| Bayer Healthcare Pharmaceuticals INC. | $19.12 | 2020 | |
| Echosens North America, INC. | $18.38 | 2025 | Fibroscan |
| Glaxosmithkline, LLC. | $17.53 | 2025 | Zejula, Jemperli |
| Abbott Laboratories | $16.00 | 2020 | |
| Novo Nordisk INC | $12.52 | 2019 | |
| Secura Bio, INC. | $12.10 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mir Ali listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.